Recent Updates
Recently added Catalysts

TDF/FTC / fixed-dose combination

Phase 3

HIV/AIDS | Small molecule | Infectious Disease |Gilead Sciences, Inc.|Last Updated: Jun 20, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment524
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05813964Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.PHASE3 RECRUITING 524Jun 5, 2024May 1, 2027Jun 20, 20254 France, Thailand
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Efficacy of F/TAF
All along the study

Number of HIV infections defined by the presence of HIV ribonucleic acid (RNA) in plasma through study completion (an average of two years) in the event-driven F/TAF arm.

Secondary Endpoints
Efficacy of F/TDF
All along the study
Acceptability of F/TAF versus F/TDF
At 1 and at 2 years of follow up.
Safety of F/TAF versus F/TDF
All along the study
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Event-driven PrEP with TDF/FTCACTIVE_COMPARATORParticipants randomly assigned to the event-driven TDF/FTC arm will be instructed to take a loading dose of two single tablets containing coformulated TDF/FTC (300/200mg) 2 to 24 hours before sexual intercourse, followed by a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourses, they will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills.
Event-driven PrEP with TAF/FTCEXPERIMENTALParticipants randomly assigned to the event-driven TAF/FTC arm will be instructed to take one single tablet containing coformulated TAF/FTC (25/200mg) with or without food 2 to 24 hours before sexual intercourse followed by a second pill 24 hours after the first drug intake. In case of daily sexual intercourses, they will be instructed to take one pill per day until the last sexual intercourse and then a last pill 24 hours later.
Interventions
NameTypeDescription
TDF/FTC 300mg/200mg fixed-dose combination tabletsDRUGEvent-driven dosing regimen
TAF/FTC 25mg/200mg fixed-dose combination tabletsDRUGEvent-driven dosing regimen.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexMALE
Healthy VolunteersYes
Study Sites4

Inclusion Criteria: * Male at birth age ≥ 18 years old * Reporting having sex with men * Negative 4th generation HIV-1 and HIV-2 test * Reporting condomless anal sex with men not more often than two days during the previous month and able to plan their sexual activity * Risk of HIV acquisition base...

Countries:FranceThailand
Unlock Eligibility Criteria